How to Cycle Peptides: What the Pharmacology Actually Supports

Search any peptide forum and you will find a “cycle”: eight weeks on, four weeks off; twelve and six; five days on, two off. These numbers are repeated with the confidence of dosing tables, but it is worth saying plainly at the outset—most of them are convention, not data. They are community heuristics that hardened into rules through repetition, not protocols read off controlled human trials. Understanding where the real pharmacology ends and the bro-science begins is the only honest way to think about “cycling.”

Where the idea of cycling actually comes from

The legitimate kernel inside cycling logic is receptor biology. When a receptor is stimulated repeatedly and intensely, the cell can blunt its own response—through receptor downregulation, desensitization, and tachyphylaxis (a diminishing effect from the same dose). For some growth-hormone–releasing peptides this is measurable. Repeated daily injection of hexarelin, a synthetic GH secretagogue, attenuates the growth-hormone response over time while also raising prolactin, adrenocorticotropin, and cortisol—so the compound is not cleanly “just GH” even at the start.^[1] That is a real pharmacological reason to limit duration: the effect you are chasing can fade, and off-target hormones can climb.

But the same literature should make anyone cautious about universal cycle lengths. Short-term administration of hexarelin—intranasal or oral—did not desensitize the GH response in older adults in one study.^[2] In other words, desensitization is dose-, route-, and duration-dependent. It is not a switch that flips at week eight. A cycle length copied from a forum cannot know which side of that line your regimen falls on, because the people who wrote it did not measure it.

Pulsatile versus continuous: the physiology worth respecting

The body releases growth hormone in bursts, not a steady stream, and this pulsatility matters. GH secretagogues and growth-hormone–releasing factors were developed and studied to work with the pituitary’s natural rhythm rather than flood it.^[3] Continuous, high-intensity stimulation is the scenario most likely to drive the desensitization described above; spacing doses or pausing them is the crude attempt to preserve a pulsatile pattern. This is the genuine physiological reasoning a thoughtful cycle gestures at— even when the specific numbers attached to it are invented.

Approved peptide drugs have dosing, not “cycles”

It is telling that the peptides which actually cleared clinical trials are dosed continuously, not cycled. Tesamorelin, a growth-hormone–releasing factor analog, was given as a fixed daily injection in its pivotal randomized trial for HIV-associated visceral fat—every day, for months, with defined dosing and monitoring, not an eight-weeks-on rotation.^[4] Sermorelin, used historically in growth-hormone evaluation and therapy, likewise has defined dosing rather than a cycle. When a compound has real efficacy and safety data behind a clinical indication, the instruction is a dose and schedule, supervised by a clinician— not a folk calendar. The presence of “cycling” in a community protocol is often a marker that the compound has never been formally dosed in people for that use at all.

The honest reasons to keep use conservative and time-limited

Strip away the false precision and a few defensible principles remain:

• Desensitization is real for some compounds. Where a peptide acts on a receptor known to downregulate—as with GH secretagogues—continuous high-dose stimulation can blunt the very response you want.^[1] Spacing or pausing doses is a reasonable hedge, even if the exact interval is unknown.
• Long-term safety data is mostly absent. Most research peptides have no long-term human safety record for these uses. Time-limited use is not a performance trick; it is a way to limit exposure to an unquantified risk.
• Off-target effects can accumulate. Hexarelin’s prolactin and cortisol rise is a concrete example of why “more, indefinitely” is a poor default.^[1]
• There is no validated universal cycle. No controlled trial has established a single on/off schedule that applies across peptides, doses, and people. Anyone presenting one as settled science is mistaken.

How to read a cycle protocol critically

When you encounter a cycle recommendation, ask three questions. First, does this specific compound have a documented desensitization or tolerance mechanism, or is it being treated like one by analogy? Second, is the schedule derived from any human data, or only from forum consensus? Third, has the compound been dosed in a real clinical trial—and if so, was it cycled or given continuously? Most of the time the honest answers are: maybe, no, and “continuously, if at all.” That does not make breaks pointless; it makes them a conservative judgment under uncertainty rather than a proven optimization.

The bottom line

Cycling sits on a small foundation of real pharmacology—receptor desensitization, pulsatile signaling, and the prudence demanded by missing long-term data—wrapped in a much larger layer of invented numbers. The legitimate instinct is to avoid relentless high-dose stimulation of a receptor that can be exhausted, and to keep exposure to under-studied compounds limited and time-bound. The illegitimate part is the precision: the idea that “8 on, 4 off” is a discovered constant rather than a guess. Treat any cycle as a hypothesis, not a prescription. Most research peptides are not FDA-approved for these purposes, decisions about them belong with a qualified clinician, and this article is educational and not medical advice.